Evidence map›Paper›PMID 37736055›Full record

ArticleOman medical journal2023

Associated Factors of Tophaceous Gout: A Study Involving 20 Primary Care Clinics in an Urbanized State in Malaysia.

Syang Pyng Gan, Mollyza Mohd Zain, Shereen Suyin Ch'ng, Hasliza Hassan, Wan Farzihan Wan Adib, Anizah Muzaid, Ing Soo Lau, Habibah Yusoof, Azmillah Rosman, Hazlyna Baharuddin

Abstract read
In one paragraph

Article in Oman medical journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Syang Pyng GanRheumatology Unit, Department of Medicine, Hospital Selayang, Selangor, Malaysia.
Mollyza Mohd ZainRheumatology Unit, Department of Medicine, Hospital Selayang, Selangor, Malaysia.
Shereen Suyin Ch'ngRheumatology Unit, Department of Medicine, Hospital Selayang, Selangor, Malaysia.
Hasliza HassanKlinik Kesihatan Sungai Pelek, Ministry of Health Malaysia, Selangor, Malaysia.
Wan Farzihan Wan AdibKlinik Kesihatan Sungai Buloh, Ministry of Health Malaysia, Selangor, Malaysia.
Anizah MuzaidKlinik Kesihatan Kuala Selangor, Ministry of Health Malaysia, Selangor, Malaysia.
Ing Soo LauRheumatology Unit, Department of Medicine, Hospital Selayang, Selangor, Malaysia.
Habibah YusoofRheumatology Unit, Department of Medicine, Hospital Selayang, Selangor, Malaysia.
Azmillah RosmanRheumatology Unit, Department of Medicine, Hospital Selayang, Selangor, Malaysia.
Hazlyna BaharuddinFaculty of Medicine, Universiti Teknologi MARA, Campus Sungai Buloh, Sungai Buloh, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Gout is a treatable disease. A complication of untreated or poorly-controlled gout is tophi formation. We conducted this study to investigate the associated factors of tophaceous gout among patients who attended 20 primary care clinics in Selangor, an urbanized state in Malaysia. Methods: We conducted a cross-sectional study from July to October 2019 that included all patients with gout who attended the clinics. Data on clinical demographics and laboratory results were collected. Comparison between tophaceous and non-tophaceous groups was performed using descriptive analysis. Results: A total of 421 patients with gout were involved in this study, 83 (19.7%) patients had visible tophi and were categorized into the tophaceous group, while the other 338 (80.3%) patients were categorized into the non-tophaceous group. The majority of patients were male with a mean age of 57.6±12.8 years. Three factors found to be significantly associated with tophaceous gout were age at symptom onset [tophaceous (45.6±13.3 years) vs. non-tophaceous (49.7±13.9 years), Conclusions: Tophaceous gout is associated with longer disease duration, higher baseline serum uric acid level, and younger age at symptoms onset. Hence, early initiation of urate-lowering therapy with a treat-to-target approach is crucial to prevent tophi formation.

Indexed as

GoutPrimary CareUric Acid

Identifiers

PMID37736055
PMCPMC10509634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.